ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Limited (ASLN) Revenue
Annual & quarterly revenue history · segment & region breakdown
ASLN · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsASLAN Pharmaceuticals Limited trailing twelve-month (TTM) revenue is $0.01B, an increase of 0.00% year-over-year from $0.01B in FY2023.
Revenue trend
2023 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.01B | +$0.01B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | -$0.00B | -100.00% |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | -$0.01B | -100.00% |
| 2016-12-31 | $0.01B | +$0.01B | — |
| 2015-12-31 | $0.00B | +$0.00B | — |
| 2014-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income ASLAN Pharmaceuticals Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
ASLAN Pharmaceuticals Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from ASLAN Pharmaceuticals Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ASLN revenue · 4 questionsASLN's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 0.00% year-over-year from $0.01B in FY2023.
▸ Source: FMP · ASLAN Pharmaceuticals Limited SEC filings · GAAP · ASLAN Pharmaceuticals Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026